R2M Pharma

R2M Pharma is a private, US-based contract research organization (CRO) and drug discovery partner specializing in oncology and small-molecule therapeutics. Operating as an extension of its clients' teams, the company leverages deep pharmaceutical industry experience to shepherd programs from early discovery to Phase 1 readiness. With a lean team of seasoned scientists led by founder Julio Medina, Ph.D., R2M focuses on creating value for partners by accelerating the delivery of robust preclinical candidates and supporting intellectual property strategy. The company appears to be a pre-revenue service provider, generating income through collaborative partnerships rather than owning its own pipeline assets.

Integrated drug discovery services platform leveraging deep medicinal chemistry expertise and a collaborative partnership model to advance small-molecule programs from hit-to-lead through preclinical development.

R2M competes in the fragmented drug discovery services market against large global CROs (e.g., WuXi AppTec, Evotec, LabCorp) and numerous boutique medicinal chemistry firms. Its differentiation is its position as a deeply integrated, strategic partner with executive-level pharmaceutical experience, rather than a transactional service provider, focusing on high-value, early-stage projects.